A Study of HNC042 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics.

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

The purpose of this First-in-Human study is to evaluate the safety , tolerability and pharmacokinetics after single ascending of HNC042 given to healthy subjects, compared to placebo. Also, the safety , tolerability and pharmacokinetics of multiple ascending of HNC042 given to healthy subjects daily for 7 days compared to placebo , will be evaluated.

Key facts

Study ID

NCT03740555

Run by

Guangzhou Henovcom Bioscience Co. Ltd.

People needed

74

Starts

2018-11-09

Expected to finish

2019-07-19

Last updated by the study team

2019-09-19

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy volunteer, age 18-56 years
• BMI between 18-34 kg/m2,and body weight not less than 50.0kg.

You may not qualify if…

• Any condition that might interfere with the procedures or tests in this study
• Drug or alcohol abuse
• Smoking

Where it is running

• Paolo B. DePetrillo — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.